Basket cover image
6 handpicked stocks

Penny Stocks to Watch

Looking for the next big thing at a small price? This carefully selected group of stocks under $5 has caught the attention of professional hedge funds. These hidden gems might offer significant growth potential for investors willing to take on some risk.

stock
stock
stock
stock
stock
Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at mai 27

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

MDIA

Mediaco Holding Inc

MDIA

Current price

$1.39

ELDN

Eledon Pharmaceuticals Inc

ELDN

Current price

$3.81

IBIO

Ibio Inc

IBIO

Current price

$0.76

About This Group of Stocks

1

Our Expert Thinking

We follow the smart money. These penny stocks have significant hedge fund holdings, leveraging the extensive research these professional investors conduct before investing. Their substantial positions may signal confidence in these companies' growth potential.

2

What You Need to Know

Penny stocks (under $5 per share) can be highly volatile but potentially rewarding. While they offer possible substantial returns, they also carry significant risks. Consider allocating only a small portion of your portfolio to these investments.

3

Why These Stocks

These specific stocks were selected because they combine the growth potential of penny stocks with the validation of hedge fund backing. Rather than random selections, each company has attracted professional investor interest despite their current low share prices.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+259.54%

Group Performance Snapshot

259.54%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 259.54% over the next year.

5 of 5

Stocks Rated Buy by Analysts

5 of 5 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🔍

Hidden Value Potential

These under-the-radar companies might be small now, but professional hedge funds have spotted something promising. Their low share prices could mean big percentage gains if they succeed.

💰

Small Investment, Big Possibilities

With share prices under $5, you can start investing with a smaller amount of money while still owning complete shares. This accessibility opens doors for investors at any level.

🧠

Smart Money Is Already In

Hedge funds have already done extensive research and invested significantly in these stocks. By following their lead, you're leveraging professional analysis that would be nearly impossible to do yourself.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.